Risk of incident diabetes after initiation of 5α-reductase inhibitor plus α-blocker combination therapy: A nationwide cohort study with age-specific analyses.
AIMS To evaluate the association between initiation of 5α-reductase inhibitor plus α-blocker combination therapy (5ARI + AB) and incident diabetes compared with α-blocker (AB) monotherapy in men with benign prostatic hyperplasia. METHODS We conducted a nationwide active-comparator, new-user cohort study using the Kor...